Joe Wolk

Joe Wolk, Chief Financial Officer of Johnson & Johnson, shares insights into the company’s recent earnings and optimistic guidance for the future. He discusses impressive growth in pharmaceuticals and MedTech, as well as new vision care technologies. Wolk highlights J&J’s strategic acquisitions, particularly in cardiovascular sectors, and the promising prospects of Kapilita in neuroscience. They also touch on how current U.S. policies are supporting life sciences investments, along with J&J's robust defense against litigation.